Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company reported a slight decline in performance, with Q1 2025 revenue at 1.608 billion yuan, down 16.53% year-on-year, and net profit attributable to shareholders at 90 million yuan, down 31.06% year-on-year. This decline is attributed to the company's ongoing channel restructuring and transformation efforts, which are currently facing transitional pressures [6] - The company is expected to achieve sequential revenue and profit growth throughout 2025, with a projected double-digit increase in net profit for the year. This growth is anticipated as the company enhances channel efficiency and brand value through its restructuring efforts [6] - The company is actively promoting its brand renewal and has launched various marketing initiatives to enhance product visibility and reach, particularly targeting younger demographics through platforms like Xiaohongshu and Bilibili [6] Financial Summary - Revenue projections for 2024 to 2027 are as follows: 8.401 billion yuan in 2024, 8.826 billion yuan in 2025 (up 5.06%), 9.770 billion yuan in 2026 (up 10.69%), and 10.753 billion yuan in 2027 (up 10.06%) [2][7] - Net profit attributable to shareholders is projected to grow from 648 million yuan in 2024 to 718 million yuan in 2025 (up 10.83%), 826 million yuan in 2026 (up 15.06%), and 962 million yuan in 2027 (up 16.39%) [2][7] - Earnings per share (EPS) is expected to increase from 0.86 yuan in 2024 to 0.95 yuan in 2025, 1.09 yuan in 2026, and 1.27 yuan in 2027 [2][7] - The price-to-earnings (P/E) ratio is projected to decrease from 17.94 in 2024 to 12.09 in 2027, indicating improving valuation metrics over the forecast period [2][7]

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [4]. Core Viewpoints - Despite short-term performance pressure due to channel transformation, the company is expected to benefit from product volume potential under the empowerment of China Resources Sanjiu, with an overall positive operational trend anticipated [4]. - The company reported Q1 2025 revenue of 1.61 billion RMB, a year-on-year decrease of 16.5%, and a net profit attributable to shareholders of 90 million RMB, down 31.1% year-on-year [2]. - The company is focusing on brand development and product volume growth, particularly with its strategic products like "Kunzhong Medicine 1381" and "777 Xuesaitong Soft Capsules" [3]. Summary by Sections Performance Review - In Q1 2025, the company achieved revenue of 1.61 billion RMB, a decrease of 16.5% year-on-year, and a net profit of 90 million RMB, down 31.1% year-on-year [2]. - The decline in performance is attributed to multiple factors, including channel transformation and the impact of national Chinese medicine procurement expansion [2]. Operational Analysis - The company is in the final phase of integration with China Resources Sanjiu, with further breakthroughs in channel transformation expected to enhance terminal coverage and performance in Q2 2025 [2]. - The focus on brand positioning as a "leading national medicine" and the emphasis on terminal coverage and sales are expected to drive healthy growth for core products [3]. Profit Forecast and Valuation - The company’s net profit forecasts for 2025, 2026, and 2027 are 740 million RMB, 893 million RMB, and 1.072 billion RMB, respectively, with year-on-year growth rates of 14%, 21%, and 20% [4]. - The expected earnings per share (EPS) for the same years are 0.98 RMB, 1.18 RMB, and 1.42 RMB, with corresponding price-to-earnings (PE) ratios of 17, 14, and 12 times [4].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [4]. Core Viewpoints - The company experienced a revenue decline of 16.5% year-on-year in Q1 2025, with total revenue reaching 1.61 billion RMB and a net profit of 90 million RMB, down 31.1% year-on-year [2]. - The integration with China Resources Sanjiu is in its final phase, and while short-term performance is under pressure due to channel transformation, there are expectations for improvement as new procurement standards are implemented in Q2 [2][4]. - The company is focusing on brand development and enhancing terminal coverage, particularly for key products like "Kunzhong Medicine 1381" and "777 Xuesaitong Soft Capsules," which are expected to see healthy growth [3]. Summary by Sections Performance Analysis - In Q1 2025, the company reported a revenue of 1.61 billion RMB, a decrease of 16.5% year-on-year, and a net profit of 90 million RMB, down 31.1% year-on-year [2]. - The decline is attributed to multiple factors, including channel transformation and the ongoing integration with China Resources Sanjiu [2]. Brand Development - The company is committed to its brand strategy, focusing on key products to strengthen its position as a leading national medicine brand [3]. - The launch of new packaging for "777 Xuesaitong" is expected to enhance brand recognition and drive sales growth [3]. Profit Forecast and Valuation - The company is projected to achieve net profits of 740 million RMB, 893 million RMB, and 1.072 billion RMB for the years 2025, 2026, and 2027, respectively, reflecting year-on-year growth rates of 14%, 21%, and 20% [4]. - The earnings per share (EPS) are expected to be 0.98 RMB, 1.18 RMB, and 1.42 RMB for the same years, with corresponding price-to-earnings (PE) ratios of 17, 14, and 12 [4].

证券代码：600422 证券简称：昆药集团 公告编号：2025-028号 昆药集团股份有限公司十一届四次监事会决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 昆药集团股份有限公司（以下简称"昆药集团"、"公司"）于 2025 年 4 月 28 日 以通讯表决方式召开公司十一届四次监事会会议。会议通知以书面方式于 2025 年 4 月 22 日发出。会议由公司监事会主席钟江先生召集并主持，本次会议应参加表决监 事 5 人，实际参加表决 5 人，符合《公司法》和《公司章程》的规定。会议审议并通 过了以下决议： 1、 关于公司 2025 年第一季度报告的议案（公司 2025 年第一季度报告刊登于上海证 券交易所网站 www.sse.com.cn） 同意：5 票 反对：0 票 弃权：0 票 监事会书面审核意见： 公司第一季度报告的编制和审议程序符合法律、法规、公司章程和公司内部管理 制度的各项规定；公司第一季度报告的内容和格式符合中国证监会和上海证券交易所 的各项规定，所包含的信息从各个方面真实地反映了公司第一季度的经营成果 ...

证券代码：600422 证券简称：昆药集团 公告编号：2025-027号 昆药集团股份有限公司十一届四次董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 昆药集团股份有限公司（以下简称"昆药集团"、"公司"）于 2025 年 4 月 28 日以通讯表决方式召开公司十一届四次董事会会议。会议通知以书面方式于 2025 年 4 月 22 日发出。会议由公司董事长吴文多先生召集并主持，本次会议应参加表决董事 9 人，实际参加表决 9 人，符合《公司法》和《公司章程》的规定。会议以记名方式投 票表决，审议并通过以下决议： 昆药集团股份有限公司董事会 2025 年 4 月 29 日 1 本议案已经公司十一届董事会审计与风险控制委员会 2025 年第三次会议审议通 过，并同意提交公司董事会审议。 同意：9 票 反对：0 票 弃权：0 票 特此公告。 1、 关于公司 2025 年第一季度报告的议案（公司 2025 年第一季度报告刊登于上海证 券交易所网站 www.sse.com.cn） ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥1,608,452,032.42, a decrease of 16.53% compared to ¥1,926,961,403.42 in the same period last year[4] - Net profit attributable to shareholders was ¥90,482,321.86, down 31.06% from ¥131,245,487.46 year-on-year[4] - The basic earnings per share decreased by 29.41% to ¥0.12 from ¥0.17 in the previous year[5] - Total operating revenue for Q1 2025 was ¥1,608,452,032.42, a decrease of 16.6% compared to ¥1,926,961,403.42 in Q1 2024[27] - Net profit for Q1 2025 was ¥113,552,441.59, a decline of 22.0% from ¥145,668,470.98 in Q1 2024[28] - Total comprehensive income for the first quarter of 2025 was CNY 114,833,485.92, a decrease from CNY 145,564,221.50 in the same period of 2024, representing a decline of approximately 21.1%[29] - Basic and diluted earnings per share for the first quarter of 2025 were CNY 0.12, down from CNY 0.17 in the first quarter of 2024, indicating a decrease of 29.4%[29] Assets and Liabilities - The total assets at the end of the reporting period were ¥12,704,524,161.69, reflecting a slight increase of 0.74% from ¥12,611,367,133.57 at the end of the previous year[5] - The company's total assets increased to ¥12,704,524,161.69 in Q1 2025 from ¥12,611,367,133.57 in Q1 2024, reflecting a growth of 0.7%[24] - Total liabilities decreased to ¥5,843,423,100.83 in Q1 2025 from ¥5,865,099,558.63 in Q1 2024, a reduction of 0.4%[23] - The company's total equity increased to ¥6,861,101,060.86 in Q1 2025 from ¥6,746,267,574.94 in Q1 2024, reflecting a growth of 1.7%[24] Cash Flow - As of March 31, 2025, the company's cash and cash equivalents amounted to approximately RMB 1.20 billion, down from RMB 2.27 billion at the end of 2024[21] - The company's cash and cash equivalents increased to ¥8,680,727,395.48 in Q1 2025, compared to ¥8,555,000,337.24 in Q1 2024, indicating a growth of 1.5%[22] - Cash inflows from operating activities totaled CNY 1,707,090,079.82 in Q1 2025, slightly up from CNY 1,700,295,070.99 in Q1 2024[33] - Cash outflows from operating activities amounted to CNY 1,846,536,508.55 in Q1 2025, compared to CNY 1,804,612,048.83 in Q1 2024, reflecting an increase of 2.3%[33] - Net cash flow from operating activities was negative CNY 139,446,428.73 in Q1 2025, worsening from negative CNY 104,316,977.84 in Q1 2024[33] - Cash inflows from investing activities were CNY 626,227,207.71 in Q1 2025, significantly higher than CNY 251,747,555.96 in Q1 2024, marking an increase of 148.5%[33] - Net cash flow from investing activities was negative CNY 1,043,720,821.02 in Q1 2025, compared to negative CNY 409,519,021.17 in Q1 2024, indicating a deterioration in investment cash flow[33] - Cash inflows from financing activities reached CNY 953,621,441.38 in Q1 2025, up from CNY 713,730,329.73 in Q1 2024, representing an increase of 33.6%[34] - The ending cash and cash equivalents balance for Q1 2025 was CNY 1,077,701,029.27, down from CNY 1,242,407,576.46 in Q1 2024, a decrease of 13.3%[34] - The company reported a significant increase in cash received from investment recoveries, totaling CNY 622,379,748.70 in Q1 2025, compared to CNY 250,000,000.00 in Q1 2024, reflecting a growth of 149.5%[33] Strategic Initiatives - The company faced challenges in sales due to a transitional period in channel dynamics and the ongoing impact of national traditional Chinese medicine procurement expansion[6] - The company is focusing on the integration with China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., aiming to enhance channel efficiency and brand penetration[10] - The "777" brand strategy is being emphasized, with the launch of new packaging for the "777 Blood Stasis Soft Capsule" to strengthen brand recognition[13] - The company is actively expanding its retail channel coverage despite pressures from the procurement expansion and retail pharmacy integration[12] - The company is committed to digital transformation in its supply chain to enhance operational efficiency and support its long-term strategic goals[11] - The company plans to focus on chronic disease management and innovation in research and development for long-term growth[14] Research and Development - The company received clinical trial approval for a new drug, KPC000154, aimed at preventing postoperative delirium, enhancing its market position in the psychiatric and neurological field[14] - The company is advancing multiple clinical trials, including the Phase I trial for KPC000154 and the Phase II trial for KYAZ01-2011-020, targeting ischemic stroke[14] - The company has made progress on its generic drug projects, with KYAH03-2020-159's application for market approval accepted for priority review by the National Medical Products Administration[14] - Research and development expenses for Q1 2025 were ¥22,356,968.35, up from ¥19,823,714.82 in Q1 2024, representing an increase of 7.7%[28] Shareholder Information - The number of common shareholders at the end of the reporting period was 36,701[16] - The largest shareholder, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., holds 212,311,616 shares, representing 28.05% of total shares[16] - The company has no related party transactions or concerted actions among its top shareholders[17] Management Changes - The company announced changes in its board and management, including the election of new board members and the appointment of a new president[18]

Investment Rating - The report maintains an "Outperform" rating for the company [4][7]. Core Insights - In 2024, the company achieved revenue of 8.40 billion RMB, a decrease of 0.34% year-on-year, while net profit attributable to shareholders was 648 million RMB, an increase of 19.86% year-on-year [4][7]. - The company adjusted its earnings per share (EPS) forecast for 2025 and 2026 to 0.97 RMB and 1.15 RMB respectively, with a new forecast for 2027 EPS at 1.38 RMB [4][7]. - The target price is set at 21.34 RMB, reflecting a 12% decrease based on an industry average valuation with a 2025 price-to-earnings (PE) ratio of 22X [4][7]. - Oral dosage forms showed stable performance with revenue of 3.69 billion RMB in 2024, up 1.18% year-on-year, while injectable products faced challenges with revenue of 539 million RMB, down 49.09% year-on-year [4][7]. - The company is undergoing deep restructuring and brand/channel remodeling, with a five-year strategic plan released under the guidance of China Resources Group [4][7]. Financial Data Summary - The company’s revenue projections for the next few years are as follows: 9.25 billion RMB in 2025, 10.17 billion RMB in 2026, and 11.22 billion RMB in 2027, reflecting growth rates of 10.1%, 10.0%, and 10.3% respectively [2][4]. - Net profit attributable to shareholders is projected to be 733 million RMB in 2025, 871 million RMB in 2026, and 1.04 billion RMB in 2027, with growth rates of 13.1%, 18.7%, and 19.9% respectively [2][4]. - The company’s return on equity (ROE) is expected to improve from 12.3% in 2024 to 15.0% in 2027 [2][4].

Financial Performance - The company's operating revenue for 2024 was approximately ¥8.40 billion, a slight decrease of 0.34% compared to ¥8.43 billion in 2023[24]. - Net profit attributable to shareholders for 2024 increased by 19.86% to approximately ¥648.08 million, up from ¥540.71 million in 2023[24]. - The net profit after deducting non-recurring gains and losses was approximately ¥419.21 million, reflecting a growth of 25.09% compared to ¥335.11 million in 2023[24]. - The net cash flow from operating activities for 2024 was approximately ¥808.07 million, an increase of 7.12% from ¥754.33 million in 2023[24]. - Total assets as of the end of 2024 reached approximately ¥12.61 billion, a 2.57% increase from ¥12.30 billion at the end of 2023[24]. - The net assets attributable to shareholders decreased by 19.94% to approximately ¥5.25 billion, down from ¥6.56 billion at the end of 2023[24]. - The basic earnings per share for 2024 was CNY 0.86, an increase of 21.13% compared to CNY 0.71 in 2023[25]. - The weighted average return on equity increased to 9.52% in 2024, up by 0.97 percentage points from 8.55% in 2023[25]. - The company achieved a historic breakthrough in overall sales scale for "Kun Traditional Medicine 1381," with core products in the digestive, emotional treatment, and respiratory categories growing by 20% year-on-year[45]. - The revenue scale of "Qingfei Huatan Wan" surpassed 100 million, while "Shu Gan Granules" and "Canling Jianpi Granules" set new historical revenue highs[45]. Strategic Initiatives - The company is focusing on the "silver hair health industry" and aims to be a leader in chronic disease management, aligning with national strategies to address aging[39]. - The company is implementing a five-year strategic development plan (2024-2028) to anchor high-quality development goals amid a complex market environment[41]. - The integration with China Resources Sanjiu is entering a critical phase, enhancing the company's operational capabilities and market positioning[41]. - The company is committed to deepening reforms and restructuring to create a patient-centered, innovation-driven, and agile organization[41]. - The company is enhancing its brand reputation and product iteration capabilities to gain a competitive advantage in the market[38]. - The company is actively participating in centralized procurement to enhance the coverage of its chronic disease product series in hospitals[50]. - The company aims to become a leader in the "silver-haired health industry" and "premium traditional Chinese medicine," focusing on the "777" brand series of oral products and the "1951" serious treatment product group for elderly health[79]. Research and Development - The company achieved a research and development investment of CNY 143.11 million, focusing on innovative drug development in the aging health sector[55]. - The company has established a comprehensive drug research and development system covering innovative drugs, generic drugs, and secondary development drugs, supported by various research platforms[83]. - The company is committed to R&D innovation, focusing on plant-based medicines and chronic disease management[70]. - The company has received approval for changes in the formulation and specifications of Dandelion granules, with the application submitted for a 24-month extension of the validity period[124]. - The company is currently developing several key pharmaceutical projects, including KYAH01-2016-079 for solid tumors in clinical phase I and KYAH01-2018-111 for non-alcoholic fatty liver disease, which has received clinical approval[123]. Market Trends and Challenges - The pharmaceutical industry is undergoing profound changes driven by policy and demand, moving towards a new stage of high-quality development[35]. - The ongoing national medical procurement is expected to lower drug prices while ensuring reasonable profit margins for pharmaceutical companies, promoting sustainable development[38]. - The aging population in China is increasing the demand for chronic disease management, with a significant rise in the prevalence of diseases such as cardiovascular diseases and diabetes among the elderly[62]. - The government has implemented policies since 2015 to promote chronic disease management, enhancing funding and encouraging social participation in healthcare services[64]. - The centralized procurement system is being expanded, with a focus on reducing drug prices and improving the quality of medical products, benefiting both patients and pharmaceutical companies[65][66]. Governance and Compliance - The company’s governance structure complies with relevant laws and regulations, ensuring the rights of all shareholders are protected[167]. - The company’s board of directors and supervisory board actively fulfill their responsibilities, ensuring compliance and oversight of financial matters[167]. - The company has implemented measures to address competition issues with its controlling shareholder, including commitments to resolve conflicts[167]. - The company is committed to maintaining independence from its controlling shareholder, ensuring no harm to the interests of the company and its shareholders[167]. - The company has conducted regular meetings to review and approve significant financial and operational decisions, ensuring transparency[171]. Future Outlook - The company aims for double-digit revenue growth in 2025, with net profit expected to match revenue growth levels[151]. - The strategic focus is on the "aging health" sector and chronic disease management, with a core emphasis on the "777" series products and "Kun Zhong Yao 1381" premium traditional Chinese medicine[149]. - The company plans to enhance its product pipeline by integrating both traditional and Western medicine, targeting a comprehensive solution for the elderly population[152]. - The company is expanding its market presence internationally, particularly in countries along the Belt and Road Initiative, and is focusing on the development of anti-malarial drugs[159].

证券代码：600422 证券简称：昆药集团 公告编号：2025-026 昆药集团股份有限公司 2025 年第三次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 4 月 18 日 (二)股东大会召开的地点：云南省昆明市国家高新技术开发区科医路 166 号昆药 集团股份有限公司管理中心 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 366 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 362,441,010 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总 | 47.8801 | | 数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议的召集、召开程序符合《中华人民共和国公司法》《上市公司股东 会规则》（下称"《股东会规则》"）及 ...

北京德恒（昆明）律师事务所 关于昆药集团股份有限公司 2025 年第三次临时股东会的 法律意见 北京德恒（昆明）律师事务所 Beijing DeHeng Law Offices (KunMing) 云南省昆明市西山区西园路 126 号"融城优郡"B5 幢 3、4 层 电话（传真）：0871-63172192 邮编: 650032 北京德恒（昆明）律师事务所 关于昆药集团股份有限公司 2025 年第三次临时股东会的 法 律 意 见 昆药集团股份有限公司： 二、关于出席本次股东会人员的资格 北京德恒（昆明）律师事务所（下称"本所"）作为贵公司的常年法律顾问， 本次指派刘书含律师、杨敏律师出席贵公司 2025 年第三次临时股东会（以下简 称"本次股东会"），并按照律师行业公认的业务标准、道德规范及勤勉尽责精 神，对贵公司提供的与本次股东会有关的文件资料进行了审查，现根据《公司法》 《证券法》《上市公司股东会规则》及贵公司《章程》的规定，就贵公司本次股 东会的相关事项出具如下法律意见： 一、关于本次股东会的召集和召开程序 根据贵公司提供的有关资料及公开披露的信息，表明贵公司董事会已于 2025 年 3 月 25 日召 ...